Ginkgolide B inhibits the neurotoxicity of prions or amyloid-β1-42
© Bate et al; licensee BioMed Central Ltd. 2004
Received: 08 March 2004
Accepted: 11 May 2004
Published: 11 May 2004
Neuronal loss in Alzheimer's or prion diseases is preceded by the accumulation of fibrillar aggregates of toxic proteins (amyloid-β1-42 or the prion protein). Since some epidemiological studies have demonstrated that the EGb 761 extract, from the leaves of the Ginkgo biloba tree, has a beneficial effect on Alzheimer's disease, the effect of some of the major components of the EGb 761 extract on neuronal responses to amyloid-β1-42, or to a synthetic miniprion (sPrP106), were investigated.
Components of the EGb 761 extract were tested in 2 models of neurodegeneration. SH-SY5Y neuroblastoma cells were pre-treated with ginkgolides A or B, quercetin or myricetin, and incubated with amyloid-β1-42, sPrP106, or other neurotoxins. After 24 hours neuronal survival and the production of prostaglandin E2 that is closely associated with neuronal death was measured. In primary cortical neurons apoptosis (caspase-3) in response to amyloid-β1-42 or sPrP106 was measured, and in co-cultures the effects of the ginkgolides on the killing of amyloid-β1-42 or sPrP106 damaged neurons by microglia was tested.
Neurons treated with ginkgolides A or B were resistant to amyloid-β1-42 or sPrP106. Ginkgolide-treated cells were also resistant to platelet activating factor or arachidonic acid, but remained susceptible to hydrogen peroxide or staurosporine. The ginkgolides reduced the production of prostaglandin E2 in response to amyloid-β1-42 or sPrP106. In primary cortical neurons, the ginkgolides reduced caspase-3 responses to amyloid-β1-42 or sPrP106, and in co-culture studies the ginkgolides reduced the killing of amyloid-β1-42 or sPrP106 damaged neurons by microglia.
Nanomolar concentrations of the ginkgolides protect neurons against the otherwise toxic effects of amyloid-β1-42 or sPrP106. The ginkgolides also prevented the neurotoxicity of platelet activating factor and reduced the production of prostaglandin E2 in response to platelet activating factor, amyloid-β1-42 or sPrP106. These results are compatible with prior reports that ginkgolides inhibit platelet-activating factor, and that platelet-activating factor antagonists block the toxicity of amyloid-β1-42 or sPrP106. The results presented here suggest that platelet-activating factor antagonists such as the ginkgolides may be relevant treatments for prion or Alzheimer's diseases.
The symptoms of Alzheimer's disease (AD), or the transmissible spongiform encephalopathies, otherwise known as the prion diseases, are thought to arise after the dysfunction or degeneration of neurons. In these diseases, extracellular aggregates of insoluble, misfolded, fibrillar proteins are thought to cause the neuronal damage. In AD, fibrils consisting of amyloid-β peptides are formed following the cleavage of the amyloid precursor protein by γ-secretases . In the prion diseases the cellular prion protein (designated PrPC) is converted into a disease-related isoforms (PrPd), in a process whereby a portion of the α-helix and random coil structure in PrPC is refolded into a β-pleated sheet .
Standard techniques to study the mechanisms of neuronal loss in vitro include incubating neuronal cells with peptides derived from the PrP protein  or from amyloid-β . The neuronal injury induced by these peptides include events characteristic of apoptosis such as surface blebbing, chromatin condensation and DNA fragmentation . In the present study we examined the neurotoxicity of fibrillar peptides by exposing the SH-SY5Y neuroblastoma cell line, or murine primary cortical neurons, to amyloid-β1-42, to a peptide derived from the human PrP protein (HuPrP82-146), or to a synthetic murine "miniprion" (sPrP106) . Further studies examined the interactions between amyloid-β1-42 or sPrP106 damaged neurons and microglia.
Extracts from the leaves of the Ginkgo biloba tree are becoming increasingly popular as a treatment that is claimed to reduce memory loss and the symptoms of mild cognitive disorders including AD. However, there remains considerable debate regarding the mechanisms of action of these preparations, or even whether such preparations have any clinical benefit. While some published studies conclude that the use of a standardized extract of the leaves of the Ginkgo biloba tree (EGb 761) reduces the symptoms of mild cognitive disorders including AD [6–8], more recent studies have failed to show clinical benefit with other preparations . In tissue culture studies the EGb 761 extract reduces amyloid-β aggregation and caspase-3 activity , and protects hippocampal neurons against amyloid-β . Since the EGb 761 extract contains many compounds including ginkgolides and the flavonoglycosides myricetin or quercetin, it is not clear which of these compounds provide the protective effect. In the present study, the main components of the EGb 761 extract were examined for their effects on SH-SY5Y neuroblastoma cells, primary cortical neurons and microglia. Low concentrations of the ginkgolides A or B were shown to protect neurons against PrP peptides or amyloid-β1-42, and to reduce microglial killing of damaged neurons.
The human neuroblastoma SH-SY5Y cell line (European Collection of Cell Cultures) was grown in RPMI-1640 culture medium supplemented with 2 mM glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin and 5% foetal calf serum (FCS). Cells were plated at 5 × 104 cells/well into 96 well plates and allowed to adhere overnight before use. Cells were pre-treated with test compounds for 3 hours before the addition of peptides and 24 hours later the survival of neurons was determined by treating cultures with WST-1 from Roche Diagnostics Ltd (Lewes, UK) for 3 hours. The amount of dye formed correlates to the number of metabolically active cells. Optical density was read on a spectrophotometer and percentage survival was calculated by reference to untreated cells incubated with WST-1 (100%). To measure prostaglandin E2 production SH-SY5Y cells were plated at 5 × 105 cells/well in 24 well plates and allowed to adhere overnight before use. Cells were treated with test compounds for 3 hours before the addition of peptides and 24 hours later prostaglandin E2 levels were determined using a competitive enzyme immunoassay kit (Amersham Biotech, UK) according to the manufacturer's instructions.
Primary neuronal cultures
Primary cortical neurons were prepared from embryonic brains as previously described . After 24 hours media was changed to neurobasal medium containing B27 components (NBM) (Invitrogen, Paisley, UK) and 2 mM glutamine. Mature cultures were pre-treated with test compounds for 3 hours before the addition of peptides; caspase-3 activity was measured using a flourometric immunosorbent enzyme assay (FIENA) kit as per the manufacturer's instructions (Roche Diagnostics, Lewes, UK) 24 hours later. For cell survival assays, microglia (prepared by dissociating the cerebral cortices of newborn 129/Ola mice as previously described ) were added to peptide treated neuronal cultures in the ratio of 1 microglia to 10 neuronal cells. Medium was replaced after 48 hours, and after 4 days microglia were removed by shaking (260 r.p.m for 30 minutes). The survival of neurons was then determined by treating cultures with WST-1.
Peptides containing amino acid residues 82 to 146 of the human PrP protein (HuPrP82-146), a control peptide (HuPrP82-146 scrambled), and a synthetic miniprion (sPrP106) derived from the murine PrP sequence were used. A peptide containing amino acids 1 to 42 of the amyloid-β protein (amyloid-β1-42) and a control peptide (amyloid-β42-1) were obtained from Bachem (St Helens, UK).
Ginkgolide B, myricetin, quercetin, staurosporine, arachidonic acid, platelet-activating factor (PAF) and hydrogen peroxide were obtained from Sigma (Poole, UK). Ginkgolide A was obtained from Calbiochem (Nottingham, UK).
Comparison of treatment effects were carried out using one and two way analysis of variance techniques as appropriate. Post hoc comparisons of means were performed as necessary.
Ginkgolide-treated neurons are resistant to PrP peptides/amyloid-β1-42
Ginkgolide-treated SH-SY5Y cells are resistant to PrP peptides/amyloid-β1-42: The survival of SHSY-5Y cells in control medium, medium containing 1 μM ginkgolides A, 1 μM ginkgolide B, 25 μM myricetin or 25 μM quercetin for 3 hours and subsequently incubated for 24 hours with 5 μM sPrP106, 10 μM HuPrP82-146 or 10 μM amyloid-β1-42. Values shown represent the percentage survival of cells compared to untreated cells. Each value is the mean ± SD from triplicate experiments repeated four times (12 observations).
100 ± 3
69 ± 4
64 ± 6
48 ± 10
101 ± 5
99 ± 3**
101 ± 2**
99 ± 4**
99 ± 3
99 ± 5**
98 ± 3**
96 ± 3**
101 ± 7
67 ± 3
65 ± 3
46 ± 5
100 ± 4
66 ± 4
66 ± 5
44 ± 5
Ginkgolides protect SH-SY5Y cells against the toxicity of PAF or arachidonic acid
Ginkgolide B-treated SH-SY5Y cells are resistant to PAF or arachidonic acid: The survival of untreated cells, and cells treated with 1 μM ginkgolide B, subsequently incubated with different neurotoxins at the concentrations shown. Values shown represent the percentage survival of treated cells compared to untreated cells. Each value is the mean ± SD from triplicate experiments repeated three times (9 observations).
ginkgolide B-treated cells
100 ± 3
98 ± 5
arachidonic acid (μM)
14 ± 2
46 ± 3**
25 ± 5
72 ± 6**
57 ± 3
93 ± 4**
hydrogen peroxide (μM)
3 ± 1
3 ± 2
7 ± 2
8 ± 2
46 ± 4
48 ± 6
18 ± 1
75 ± 7**
37 ± 2
97 ± 3**
62 ± 3
100 ± 2**
40 ± 3
38 ± 3
72 ± 4
69 ± 2
93 ± 3
95 ± 3
Prostaglandin E2 production in ginkgolide treated cells
Ginkgolides reduce prostaglandin E2 production: Levels of prostaglandin E2 produced by untreated SH-SY5Y cells, or cells pre-treated with 1 μM ginkgolide A, 1 μM ginkgolide B, 25 μM myricetin or 25 μM quercetin and thereafter incubated for 24 hours with 10 μM arachidonic acid, 10 μM amyloid-β1-42 10 μM HuPrP82-146 or 5 μM PAF. Each value is the mean level of prostaglandin E2 (pg/ml) ± SD from triplicate experiments repeated three times (9 observations).
362 ± 46
323 ± 39
438 ± 55
157 ± 38
66 ± 40**
57 ± 40**
234 ± 34**
45 ± 29**
25 ± 27**
145 ± 30**
36 ± 26**
358 ± 64
327 ± 36
450 ± 30
149 ± 28
349 ± 51
319 ± 28
442 ± 45
169 ± 29
Ginkgolides reduce caspase-3 activity in primary cortical neurons
Cellular lysates were prepared from primary cortical neurons incubated with 5 μM sPrP106 or 10 μM amyloid-β1-42 and tested for caspase-3 activity as a measure of apoptosis. Caspase-3 activity in cells treated with sPrP106 (6.9 ± 1.1 AFC units, n = 6) was significantly reduced by pre-treatment with 1 μM ginkgolide B (1.2 ± 1.3, p < 0.05). Similarly, pre-treatment with 1 μM ginkgolide B reduced the caspase-3 activity of neurons incubated with amyloid-β1-42 (5.7 ± 1.2 v 1.5 ± 0.5, p < 0.05). Pre-treating cells with myricetin or quercetin did not alter caspase-3 activity. In further studies primary cortical neurons treated with 1 μM ginkgolide B were resistant to the toxicity of sPrP106 or amyloid-β1-42 (data not shown).
Microglial killing of PrP damaged neurons is blocked by ginkgolides
In the present study the affects of individual components of the EGb 761 extract on some of the pathological processes that occur during AD or prion diseases were examined. Although previous studies suggest that the flavonoglycosides had protective properties against oxidative stress in vitro , we were unable to demonstrate a protective effect of myricetin or quercetin against PrP peptides or amyloid-β1-42. Moreover, recent studies reported that these flavonoglycosides have limited bioavailability after oral administration  raising doubts as to whether such compounds are responsible for the protective effects of the EGb 761 extract. In contrast, both ginkgolides A and B prevented neuronal death in response to sPrP106, PrP peptides or to amyloid-β1-42. The protective effects of the ginkgolides were dose-dependent, and both the ginkgolides protected neurons at nanomolar concentrations. Moreover, we found no evidence that the protective effect of the ginkgolide B could be overcome by increasing the concentration of sPrP106 or amyloid-β1-42. In AD and prion diseases the loss of neurons in vivo occurs though apoptosis [3, 20], and although fibrillar PrP/amyloid-β peptides kill neurons in vitro the mechanisms that activate neuronal apoptosis remain unknown. In the present study both sPrP106 and amyloid-β1-42 induced caspase-3, a marker of apoptosis that is increased in murine scrapie  and AD . The presence of ginkgolides greatly reduced the activation of apoptotic pathways in these cells. The presence of ginkgolides also reduced microglial killing of neurons damaged by sPrP106 or amyloid-β1-42. Microglia respond to changes in neurons induced by PrP peptides  and our data are compatible with the hypothesis that pre-treatment with the ginkgolides prevents the PrP-induced changes that activate microglia.
It is worth noting that for many Ginkgo biloba extracts, extraction procedures are used that optimise the flavonoglycoside content. However, these procedures may result in extracts that contain different amounts of ginkgolides. Variations in the ginkgolide content of different extracts may be a factor in the variability of results obtained in clinical studies. The ginkgolides inhibit the activity of PAF  that is produced in neurons via the remodeling pathway , and a recent study showed that PAF antagonists protect neurons against the toxicity of PrP or amyloid-β peptides . In the present study ginkgolide treated cells were resistant to the toxicity of PAF as well as that of PrP peptides or amyloid-β1-42. It was noteworthy that ginkgolide B was consistently stronger than that of ginkgolide A, consistent with prior reports that ginkgolide B has greater PAF antagonism than ginkgolide A .
Further studies were designed to determine how antagonism of PAF might prevent the toxicity of PrP or amyloid-β peptides. Levels of prostaglandin E2 (a measure of COX activity) are increased in the cerebrospinal fluid of patients with either Creutzfeldt-Jakob disease  or AD . A causative role for prostaglandins in neurotoxicity was strengthened by in vitro observations that neurons treated with COX inhibitors, the enzymes that convert arachidonic acid to prostaglandins, are also resistant to prions  or amyloid-β1-42 . These results are compatible with epidemiological data that show that the use of COX inhibitors reduces the onset and severity of AD . In the present study the addition of PAF stimulated the production of prostaglandin E2 from neuronal cells suggesting that it activates neuronal COX. Furthermore, the ginkgolides reduced prostaglandin E2 production after the addition of arachidonic acid or PAF, as well as in response to PrP or amyloid-β peptides, and cells pre-treated with ginkgolide B were partially resistant to the toxicity of arachidonic acid. These results are compatible with the hypothesis that ginkgolides modulate the COX related production of toxic prostaglandins. It is worth noting that in cell free systems the ginkgolides did not affect the conversion of arachidonic acid to prostaglandins showing they did not have a direct effect on neuronal COX (data not shown).
The present study showed that neurons treated with nanomolar concentrations ginkgolides A or B are resistant to the otherwise toxic effects PrP peptides or amyloid-β1-42. This protective effect coincided with reduced neuronal prostaglandin E2 production indicating that neuronal COX was impaired, compatible with previous observations that COX inhibitors protected neurons against PrP peptides  or amyloid-β1-42 . However, unlike aspirin or ibuprofen, the ginkgolides did not have a direct effect on COX enzymes. The protective effect of the ginkgolides in vitro correlated with their ability to inhibit PAF . These compounds also prevented amyloid-β1-42 or sPrP106 treated neurons activating microglia resulting in increased neuronal survival in co-cultures. Recent studies showed that the bioavailability of ginkgolides after oral administration is high , although studies to determine if the ginkgolides cross the blood brain barrier and penetrate the central nervous system are still forthcoming. These results suggest that the ginkgolides have the potential to reduce neuronal loss in prion diseases or AD. However, the processes that underlie neuronal loss in prion or Alzheimer's diseases are varied and more complex than the simple model of neurodegeneration presented here, and further study is required to evaluate the benefits of these compounds.
List of abbreviations
- Alzheimer's disease (AD):
cyclo-oxygenases (COX), a standardized extract of the leaves of the Ginkgo biloba tree (EGb 761), fetal calf serum (FCS), flourometric immunosorbent enzyme assay (FIENA), a peptide containing amino acid residues 82 to 146 of the human PrP protein (HuPrP82-146), platelet activating factor (PAF), cellular prion protein (PrPC), disease-associated isoform of the prion protein (PrPd), synthetic miniprion (sPrP106).
This work was supported by a grant from the European Commission (QLK3-CT-2001-00283), the Italian Ministry of Health (RF 2001.96) and the Italian Ministry of University and Research (PRIN 2001).
- Esler WP, Wolfe MS: A portrait of Alzheimer secretases – new features and familiar faces. Science. 2001, 293: 1449-1454. 10.1126/science.1064638.View ArticlePubMed
- Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, Melhorn I, Huang Z, Fletterick RJ, Cohen FE: Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci U S A. 1993, 90: 10962-10966.PubMed CentralView ArticlePubMed
- Forloni G, Angeretti N, Chiesa R, Monzani E, Salmona M, Bugiani O, Tagliavini F: Neurotoxicity of a prion protein fragment. Nature. 1993, 362: 543-546. 10.1038/362543a0.View ArticlePubMed
- Yankner BA, Dawes LR, Fisher S, Villa-Komaroff L, Oster-Granite ML, Neve RL: Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science. 1989, 245: 417-420.View ArticlePubMed
- Bonetto V, Massignan T, Chiesa R, Morbin M, Mazzoleni G, Diomede L, Angeretti N, Colombo L, Forlomi G, Tagliavini F, Salmona M: Synthetic miniprion PrP106. J Biol Chem. 2002, 277: 31327-31334. 10.1074/jbc.M203275200.View ArticlePubMed
- Oken BS, Storzbach DM, Kaye JA: The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol. 1998, 55: 1409-1415. 10.1001/archneur.55.11.1409.View ArticlePubMed
- Le Bars PL, Velasco FM, Ferguson JM, Dessain EC, Kieser M, Hoerr R: Influence of the severity of cognitive impairment on the effect of the Gnkgo biloba extract EGb 761 in Alzheimer's disease. Neuropsychobiology. 2002, 45: 19-26. 10.1159/000048668.View ArticlePubMed
- Mix JA, Crews WD: A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings. Hum Psychopharmacol. 2002, 17: 267-277. 10.1002/hup.412.View ArticlePubMed
- Solomon PR, Adams F, Silver A, Zimmer J, DeVeaux R: Ginkgo for memory enhancement: a randomized controlled trial. JAMA. 2002, 288: 835-840. 10.1001/jama.288.7.835.View ArticlePubMed
- Luo Y, Smith JV, Paramasivam V, Burdick A, Curry KJ, Buford JP, Khan I, Netzer WJ, Xu H, Butko P: Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci U S A. 2002, 99: 12197-12202. 10.1073/pnas.182425199.PubMed CentralView ArticlePubMed
- Bastianetto S, Ramassamy C, Dore S, Christen Y, Poirier J, Quirion R: The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur J Neurosci. 2000, 12: 1882-1890. 10.1046/j.1460-9568.2000.00069.x.View ArticlePubMed
- Bate C, Boshuizen RS, Langeveld JP, Williams A: Temporal and spatial relationship between the death of PrP-damaged neurones and microglial activation. Neuroreport. 2002, 13: 1695-1700. 10.1097/00001756-200209160-00025.View ArticlePubMed
- Aihara M, Ishii S, Kume K, Shimizu T: Interaction between neurone and microglia mediated by latelet-activating factor. Genes Cells. 2000, 5: 397-406. 10.1046/j.1365-2443.2000.00333.x.View ArticlePubMed
- Bate C, Rutherford S, Gravenor M, Reid S, Williams A: Cyclo-oxygenase inhibitors protect against prion-induced neurotoxicity in vitro. Neuroreport. 2002, 13: 1933-1938. 10.1097/00001756-200210280-00021.View ArticlePubMed
- Bate C, Veerhuis R, Eikelenboom P, Williams A: Neurones treated with cyclo-oxygenase-1 inhibitors are resistant to amyloid-beta1-42. Neuroreport. 2003, 14: 2099-2103. 10.1097/00001756-200311140-00018.View ArticlePubMed
- Brown DR, Schmidt B, Kretzschmar HA: Role of microglia and host prion protein in neurotoxicity of a prion protein fragment. Nature. 1996, 380: 345-347. 10.1038/380345a0.View ArticlePubMed
- Meda L, Cassatella MA, Szendrei GI, Otvos LJ, Baron P, Villalba M, Ferrari D, Rossi F: Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature. 1995, 374: 647-650. 10.1038/374647a0.View ArticlePubMed
- Oyama Y, Fuchs PA, Katayama N, Noda K: Myricetin and quercetin, the flavonoid constituents of Ginkgo biloba extract, greatly reduce oxidative metabolism in both resting and Ca(2+)-loaded brain neurons. Brain Res. 1994, 635: 125-129. 10.1016/0006-8993(94)91431-1.View ArticlePubMed
- DeFeudis FV, Drieu K: Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets. 2000, 1: 25-58.View ArticlePubMed
- Kitamura Y, Shimohama S, Kamoshima W, Ota T, Matsuoka Y, Nomura Y, Smith MA, Perry G, Whitehouse PJ, Taniguchi T: Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease. Brain Res. 1998, 780: 260-269. 10.1016/S0006-8993(97)01202-X.View ArticlePubMed
- Jamieson E, Jeffrey M, Ironside JW, Fraser JR: Activation of Fas and caspase 3 precedes PrP accumulation in 87 V scrapie. Neuroreport. 2001, 12: 3567-3572. 10.1097/00001756-200111160-00039.View ArticlePubMed
- Stadelmann C, Deckwerth TL, Srinivasan A, Bancher C, Bruck W, Jellinger K, Lassmann H: Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. Am J Pathol. 1999, 155: 1459-1466.PubMed CentralView ArticlePubMed
- Oberpichler H, Sauer D, Rossberg C, Mennel HD, Krieglstein J: PAF antagonist ginkgolide B reduces postischemic neuronal damage in rat brain hippocampus. J Cereb Blood Flow Metab. 1990, 10: 133-135.View ArticlePubMed
- Bate C, Salmona M, Williams A: The role of platelet activating factor in prion and amyloid-β neurotoxicity. Neuroreport. 2004, 15: 509-513. 10.1097/00001756-200403010-00025.View ArticlePubMed
- Korth R, Nunez D, Bidault J, Benveniste J: Comparison of three paf-acether receptor antagonist ginkgolides. Eur J Pharmacol. 1988, 152: 101-110. 10.1016/0014-2999(88)90840-0.View ArticlePubMed
- Minghetti L, Cardone F, Greco A, Puopolo M, Levi G, Green AJ, Knight R, Pocchiari M: Increased CSF levels of prostaglandin E(2) in variant Creutzfeldt-Jakob disease. Neurology. 2002, 58: 127-129.View ArticlePubMed
- Montine TJ, Sidell KR, Crews BC, Markesbery WR, Marnett LJ, Roberts LJ, Morrow JD: Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology. 1999, 53: 1495-1498.View ArticlePubMed
- McGeer PL, Schulzer M, McGeer EG: Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 1996, 47: 425-432.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.